drugset
drugset / Trial / NCT00151827

Olmesartan Medoxomil in Hypertension and Renal Impairment

NCT00151827 ↗

Phase 3 Completed 393 enrolled Sankyo Pharma Gmbh
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study in hypertensive patients with mild to moderate renal impairment. The antihypertensive efficacy of olmesartan medoxomil is compared to losartan.

Timeline

Start
2003-08
Primary completion
2005-07
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Losartan Other / unclassified 50 mg Oral
Subject Losartan Other / unclassified 100 mg Oral
Subject Olmesartan medoxomil Unknown 20 mg Oral
Subject Olmesartan medoxomil Unknown 40 mg Oral
Background Furosemide Other / unclassified 20 mg Oral
Background Furosemide Other / unclassified 120 mg Oral

Indications

essential hypertension impaired renal function disease